Outpacing market growth, EBIT before incidentals increased 2% to EUR 213 million, resulting in an EBIT margin of 18.9%. Divestments and acquisitions had a negative impact on revenues of 3%.
In Europe, autonomous growth was 5%, while in North America, revenues from ongoing operations grew 12%. At the end of the year, Intervet received important product approvals for Zilmax, a feed additive for cattle and PreveNile, a West Nile Virus vaccine for horses.
In Europe, autonomous growth was 5%, while in North America, revenues from ongoing operations grew 12%. At the end of the year, Intervet received important product approvals for Zilmax, a feed additive for cattle and PreveNile, a West Nile Virus vaccine for horses.
